Profile data is unavailable for this security.
About the company
Pila Pharma AB is a Sweden-based clinical stage pharmaceutical company, active in the biotechnology sector. The Company conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.
- Revenue in SEK (TTM)1.46m
- Net income in SEK-9.93m
- Incorporated2014
- Employees1.00
- LocationPila Pharma ABVastergatan 1MALMO 211 21SwedenSWE
- Websitehttps://pilapharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lipigon Pharmaceuticals AB | 16.41m | -12.71m | 35.15m | -- | -- | 1.64 | -- | 2.14 | -0.2459 | -0.2459 | 0.2138 | 0.1694 | 1.07 | -- | 21.49 | -- | -83.21 | -314.67 | -137.73 | -426.49 | -- | -- | -77.44 | -488.14 | -- | -- | 0.00 | -- | -- | 444.44 | 67.83 | -- | -- | -- |
Oncozenge AB | 0.00 | -14.22m | 43.05m | -- | -- | 2.65 | -- | -- | -1.21 | -1.21 | 0.00 | 1.39 | 0.00 | -- | -- | -- | -58.23 | -- | -61.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
Elicera Therapeutics AB | 12.85m | -19.50m | 46.15m | 2.00 | -- | 1.46 | -- | 3.59 | -0.9726 | -0.9726 | 0.6416 | 0.901 | 0.3015 | -- | 11.43 | 6,426,955.00 | -45.75 | -40.06 | -62.75 | -49.74 | -- | -- | -151.72 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
Lipidor AB | 87.00k | -11.59m | 51.32m | -- | -- | -- | -- | 589.93 | -0.1049 | -0.1049 | 0.0008 | -0.0817 | 0.0122 | -- | 0.19 | -- | -162.65 | -59.41 | -- | -75.10 | -- | -- | -13,322.99 | -643.36 | -- | -- | -- | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
Ziccum AB | 6.64m | -20.50m | 84.55m | 9.00 | -- | 6.45 | -- | 12.74 | -1.46 | -1.46 | 0.4721 | 0.8534 | 0.2696 | -- | 22.01 | 829,375.00 | -83.29 | -68.51 | -106.42 | -76.47 | -- | -- | -308.94 | -2,598.03 | -- | -- | 0.0516 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
Odi Pharma AB (publ) | 14.80m | -1.67m | 105.78m | -- | -- | 30.31 | -- | 7.15 | -0.1097 | -0.1097 | 0.9727 | 0.2293 | 1.36 | 18.13 | 3.94 | -- | -15.36 | -- | -39.25 | -- | -25.26 | -- | -11.27 | -- | 1.26 | -2.31 | 0.00 | -- | -55.44 | -- | 4.67 | -- | -- | -- |
StenoCare A/S | 6.25m | -25.60m | 110.30m | 9.00 | -- | 3.23 | -- | 17.65 | -1.13 | -1.13 | 0.2674 | 1.22 | 0.1285 | -- | 2.94 | -- | -52.62 | -28.16 | -70.34 | -35.47 | -- | -- | -409.55 | -371.06 | 1.04 | -5.56 | 0.2362 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
Isofol Medical AB (publ) | 0.00 | -31.16m | 111.12m | 4.00 | -- | 0.9838 | -- | -- | -0.1964 | -0.1964 | 0.00 | 0.6993 | 0.00 | -- | -- | 0.00 | -20.49 | -66.73 | -24.10 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
Pila Pharma AB | 1.46m | -9.93m | 115.40m | 1.00 | -- | 17.32 | -- | 78.88 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
ExpreS2ion Biotech Holding AB | 7.77m | -77.95m | 124.52m | 18.00 | -- | 1.29 | -- | 16.03 | -1.33 | -1.33 | 0.129 | 0.8696 | 0.0821 | -- | 4.87 | 298,730.80 | -82.36 | -63.54 | -113.92 | -75.88 | -132.91 | -1.94 | -1,003.55 | -524.31 | -- | -- | 0.0055 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
Vivesto AB | 0.00 | -116.73m | 144.20m | 6.00 | -- | 0.7615 | -- | -- | -0.219 | -0.219 | 0.00 | 0.352 | 0.00 | -- | -- | 0.00 | -44.08 | -- | -47.15 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
Enorama Pharma AB | 670.00k | -42.47m | 165.74m | 5.00 | -- | 7.02 | -- | 247.38 | -1.03 | -1.03 | 0.0163 | 0.4271 | 0.0184 | 0.7583 | 0.6384 | 134,000.00 | -116.48 | -73.56 | -184.45 | -104.85 | -635.07 | 43.36 | -6,338.66 | -557.42 | 0.4626 | -605.70 | 0.02 | -- | -80.17 | -23.71 | -6.15 | -- | -- | -- |
Lipum AB (publ) | 0.00 | -39.32m | 179.25m | 5.00 | -- | -- | -- | -- | -4.44 | -4.44 | 0.00 | -0.49 | 0.00 | -- | -- | 0.00 | -247.63 | -127.85 | -402.13 | -184.50 | -- | -- | -- | -293,228.70 | -- | -- | -- | -- | -- | -- | 2.38 | -- | -- | -- |